Form 4: Pfizer Executive Vice President Acquires Stock Appreciation Rights

Executive Vice President Michael McDermott acquired stock appreciation rights convertible to Pfizer common stock, according to a Form 4 filing.

Summary

• Michael McDermott, an Executive Vice President at Pfizer Inc., reported a transaction on March 4, 2025.
• McDermott acquired 289,196 stock appreciation rights (SARs) at a price of $25.75.
• These SARs are subject to vesting requirements and will be settled in shares of Pfizer common stock on March 4, 2030, the fifth anniversary of the grant date.
• Following the transaction, McDermott directly owns 289,196 derivative securities.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, indicating a neutral sentiment. It simply reports a transaction.

Future Outlook

The stock appreciation rights will be settled in shares of Pfizer common stock on the fifth anniversary of the grant date, subject to vesting requirements.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like executives and directors, trade their company's stock. These filings provide transparency into insider transactions and are closely watched by investors.

Stakeholder Impact

• The transaction could have a minor impact on shareholders by slightly increasing the number of shares outstanding in the future when the stock appreciation rights are exercised.

Key Dates